Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rAAV9-CMV-hNAGLUop Gene Therapy for MPS IIIB
NCT07818759Phase 2Not yet recruiting
- Sponsor
- NeuroGT
- Start
- Jan 2027
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of NGT-104 in mucopolysaccharidosis type IIIB, sponsored by NeuroGT. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
NGT-104
03
Conditions
mucopolysaccharidosis type IIIB
Beyond the preview
Go deeper on NCT07818759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07818759.